Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acrivastine plus Clarityne for chronic intractable urticaria
ChiCTR-IPR-17011515Phase 4Recruiting
- Sponsor
- Department of Dermatology, Beijing Friendship Hospital, Capital Medical University
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of acrivastine and loratadine in urticaria (3 arms), sponsored by Department of Dermatology, Beijing Friendship Hospital, Capital Medical University. Primary endpoints: Dermatology Life Quality Index (DLQI), Patient global assessment of disease severity and 1 more. Started May 2017; status: recruiting.
02
Drugs
acrivastineloratadine
03
Conditions
urticaria
Beyond the preview
Go deeper on ChiCTR-IPR-17011515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011515.